Insider Buying: Oxford Biomedica (LON:OXB) Insider Buys £102,262.50 in Stock

Oxford Biomedica plc (LON:OXB – Get Free Report) insider Roch Doliveux bought 20,250 shares of Oxford Biomedica stock in a transaction on Wednesday, September 23rd. The shares were bought at an average price of GBX 505 per share, for a total transaction of £102,262.50.

Oxford Biomedica Stock Performance

Shares of OXB stock opened at GBX 507 on Friday. The stock has a 50-day moving average of GBX 506.56 and a 200-day moving average of GBX 574.62. Oxford Biomedica plc has a one year low of GBX 420 and a one year high of GBX 952. The stock has a market cap of £613.71 million, a PE ratio of -18.83 and a beta of 1.09. The company has a debt-to-equity ratio of 273.08, a current ratio of 2.21 and a quick ratio of 1.67.

Get Oxford Biomedica alerts:

Oxford Biomedica (LON:OXB – Get Free Report) last released its quarterly earnings data on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) EPS for the quarter. Oxford Biomedica had a negative return on equity of 54.51% and a negative net margin of 23.23%. As a group, sell-side analysts expect that Oxford Biomedica plc will post -31.0799998 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Jefferies Financial Group restated a “buy” rating and set a GBX 8.27 price objective on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a GBX 595 price target on shares of Oxford Biomedica in a research note on Wednesday, September 2nd. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a GBX 900 price objective on shares of Oxford Biomedica in a research report on Tuesday, September 1st. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 580.85.

Get Our Latest Stock Analysis on OXB

Oxford Biomedica Company Profile

(Get Free Report)

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.

Featured Stories

• Five stocks we like better than Oxford Biomedica
• 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
• SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
• These 3 Overlooked Stocks Have Big Money Behind Them
• Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally

Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.